Christopher D Byrne

Christopher D Byrne is an expert in Hepatology at University Hospital Southampton NHS Foundation Trust (United Kingdom). As of October 2026, ScienceLeadR ranks Christopher D Byrne in the top 1% of experts worldwide for MASH, Alcohol-Induced Disorders and Metabolic Syndrome. Christopher D Byrne has authored 668 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 1 of them ongoing. SLR score: 2,573 (community average: 125). How the SLR is computed.

Hepatology

Subspecialties: Gastroenterology - Endocrinology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 24, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1994 - 2026

Source: PubMed

University of Southampton

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 668

Citations

Citations: 44 055 1st author: 51 Last author: 193 Unique author: 24

Main journals

Best Journals

Lancet Gastroenterol Hepatol 10

Nat Rev Gastroenterol Hepatol 9

J Hepatol 7

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year	Citations
Metabolic Dysfunction-Associated Steatotic Liver Disease in Children and Adolescents. PMID 42905722 — liver diseases, liver, adolescent, child	JAMA Top journal	2026	0
Metabolic dysfunction-associated steatotic liver disease (MASLD) versus metabolic dysfunction and alcohol-associated steatotic liver disease (Met-ALD), do the differences matter in clinical practice? PMID 42872032 — liver diseases, liver	Hepatobiliary Surg Nutr	2026	0
Erratum. Sodium-Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies. Diabetes Care 2025;48:1042-1052. PMID 42873906 — diabetes mellitus, sodium-glucose transport proteins, cohort studies, liver, diabetes mellitus, type 2	Diabetes Care	2026	0
Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework. PMID 42717057 — heart, cardiovascular diseases, liver	Nat Rev Gastroenterol Hepatol Top journal	2026	1
Body composition in glucagon-like peptide-1 receptor agonist therapy: Absolute loss, relative changes, and outcomes. PMID 42601996 — glucagon-like peptide 1, glucagon-like peptide-1 receptor, body composition, glucagon, therapeutics, glucagon-like peptides	Hepatol Forum	2026	0

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

N/A 4

Phase 2 1

Phase 3 1

Phase 4 1

By status:

Completed 6

Recruiting 1

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 4

multicentric2to4 2

multicentric5to9 0

multicentricup10 1

Main Topics

Digestive System Diseases 3

Nutritional and Metabolic Diseases 3

Endocrine System Diseases 2

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
PRIORITY CONNECT 2 Pilot Trial NCT06212700 — exercise, comorbidity, pilots, pancreatic neoplasms, psychology, muscles, malnutrition, pain, caregivers, nursing, neoplasms, preoperative exercise, liver, gastrointestinal neoplasms, pancreas, liver neoplasms, smoking cessation, muscle strength, walking, colorectal neoplasms, education, respiratory muscles, smoking, alcohol drinking, stomach neoplasms, postoperative complications	N/A	Recruiting	2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice